

1 **Comparative molecular and immunoregulatory analysis of**  
2 **extracellular vesicles from *Candida albicans* and *Candida auris*.**

3 Daniel Zamith-Miranda <sup>1, 2</sup>, Heino M. Heyman <sup>3</sup>, Sneha P. Couvillion <sup>3</sup>, Radames J. B.  
4 Cordero <sup>4</sup>, Marcio L. Rodrigues <sup>5, 6</sup>, Leonardo Nimrichter <sup>6</sup>, Arturo Casadevall <sup>4</sup>, Rafaela  
5 F. Amatuzzi <sup>5</sup>, Lysangela R. Alves <sup>5</sup>, Ernesto S. Nakayasu <sup>3,\*</sup>, Joshua D. Nosanchuk <sup>1,2,\*</sup>

6 **Affiliations**

7 1- Department of Microbiology and Immunology, Albert Einstein College of Medicine,  
8 Bronx, New York, USA

9 2- Division of Infectious Diseases, Department of Medicine, Albert Einstein College of  
10 Medicine, Bronx, New York, USA

11 3- Biological Sciences Division, Pacific Northwest National Laboratory, Richland,  
12 Washington, USA

13 4- Harry Feinstone Molecular Microbiology and Immunology Department, Johns  
14 Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA

15 5- Carlos Chagas Institute, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil

16 6- Microbiology Institute Paulo de Góes (IMPG), Federal University of Rio de Janeiro,  
17 Rio de Janeiro, Brazil

18 \*ESN and JDN share senior authorship

19 **Correspondence authors:** Ernesto S. Nakayasu ([ernesto.nakayasu@pnnl.gov](mailto:ernesto.nakayasu@pnnl.gov)) and  
20 Joshua D. Nosanchuk ([josh.nosanchuk@einsteinmed.org](mailto:josh.nosanchuk@einsteinmed.org))

21 **Keywords:** *Candida auris*, *Candida albicans*, extracellular vesicles, multi-omics, fungal  
22 pathogenesis, *candidiasis*.

23 **Abstract**

24 *Candida auris* is a recently described multidrug-resistant pathogenic fungus that is  
25 increasingly responsible for healthcare associated outbreaks across the world.  
26 Bloodstream infections of this fungus cause death in up to 70% of the cases.  
27 Aggravating this scenario, *C. auris*' disease-promoting mechanisms are poorly  
28 understood. Fungi release extracellular vesicles (EVs) carrying a broad range of  
29 molecules including proteins, lipids, carbohydrates, pigments, and RNA, many of which  
30 are virulence factors. Here, we carried out a comparative molecular characterization of  
31 *C. auris* and *C. albicans* EVs and evaluated their capacity to modulate effector  
32 mechanisms of host immune defense. Using proteomics, lipidomics, and  
33 transcriptomics, we found that *C. auris* released EVs with payloads that were  
34 significantly different from EVs released by *C. albicans*. EVs released by *C. auris*  
35 potentiated the adhesion of this yeast to an epithelial cell monolayer, while EVs from *C.*  
36 *albicans* had no effect. *C. albicans* EVs primed macrophages for intracellular yeast  
37 killing, whereas *C. auris* EVs promoted survival of the fungal cells. Moreover, EVs from  
38 both *C. auris* and *C. albicans* induced the activation of bone marrow-derived dendritic  
39 cells. Altogether, our findings show distinct profiles and properties of EVs released by *C.*  
40 *auris* and by *C. albicans*, and highlight the potential contribution of *C. auris* EVs to the  
41 pathogenesis of this emerging pathogen.

42 **Importance**

43 *Candida auris* is a recently described multi-drug resistant pathogenic fungus that is  
44 responsible for outbreaks across the globe, particularly in the context of nosocomial  
45 infections. Its virulence factors and pathogenesis are poorly understood. In the current  
46 work, we tested the hypothesis that extracellular vesicles (EVs) released by *C. auris* is a  
47 disease-promoting factor . In this manuscript, we described the production of EVs by *C.*  
48 *auris* and compared their biological activities against the better-characterized EVs from  
49 *C. albicans*. *C. auris* EVs have immunoregulatory properties, of which some are  
50 opposite of *C. albicans* EVs. We also explored the cargo and structural components of  
51 those vesicles and found that they are remarkably distinct than EVs from its  
52 phylogenetic relative *Candida albicans*.

53

#### 54 **Introduction**

55 *Candida auris* is a recently described pathogenic fungus that has emerged as a serious  
56 cause of healthcare associated infections across the world (1). Therefore, it is  
57 considered a global threat by the US Center for Disease Control and Prevention (2).  
58 The biological challenges for combatting *C. auris* include the fungus' capacity to form  
59 resilient biofilms and to resist multiple antifungal drugs (3). *C. auris* kills 30-70% of the  
60 infected individuals (4). Although we have deep knowledge regarding the disease-  
61 promoting mechanisms deployed by other *Candida* species, relatively little is known  
62 about *C. auris*. We have recently compared the molecular profiles of two *C. auris*  
63 isolates vs. *Candida albicans* by integrating proteins, lipids, and metabolites of these  
64 yeast cells, and demonstrated that *C. auris* has an elevated expression of pathways  
65 related to drug resistance and virulence, such as sterol metabolism and drug  
66 resistance-related transporters (5).

67 Disease development is a combination of fungal virulence factors and the affected  
68 host's ability to efficiently control the fungal growth, and extracellular vesicles (EVs) play  
69 a role in both of these factors. EVs are lipid bilayered structures released by a broad  
70 variety of uni- or multicellular organisms (6). Fungal EVs from *Cryptococcus*  
71 *neoformans* were first described in 2007 (7) and they have since been shown as an  
72 important mechanism for molecular export in a variety of fungal species. EVs produced  
73 by fungi carry many biologically active molecules, including virulence factors and  
74 regulators, indicating that they could activate the innate immune system and influence  
75 disease development (8-16). *In vitro*, fungal EVs impact phagocyte activity, promoting  
76 an increase in cytokine levels, modulating phagocytosis and regulating macrophage  
77 polarization (8-10, 14, 16, 17). Together, these data strongly suggest that fungal EVs  
78 activate the immune response. Indeed, *Galleria mellonella* larvae are protected by pre-  
79 treatment with EVs from *C. albicans*, *C. neoformans* and *Aspergillus flavus* (9, 18, 19).  
80 Recently, we demonstrated that immunization of mice with EVs from *C. albicans* confers  
81 full protection against systemic candidiasis (11).

82 However, the outcome of fungal EV and host response depends on the model  
83 investigated. For instance, yeast EVs released from co-cultures of dendritic cells (DCs)  
84 and *Malassezia sympodialis* induce the production of TNF- $\square$  and higher levels of IL-4 by  
85 PBMC from patients with atopic eczema, when compared to control PBMC, displaying  
86 an allergic reaction (20, 21). *C. neoformans* and *Sporothrix brasiliensis* EVs are  
87 associated with virulence and disease progress in murine models, respectively (22, 23).  
88 We hypothesize that the multiple activities attributed to fungal EVs could be dependent  
89 on their composition, which at least partially differs according to the species investigated

90 (9, 21, 24-29). Thus, a more complete analysis on EVs composition could open new  
91 views for understanding fungal diseases.

92 Here, we performed a detailed characterization of EVs released by two distinct strains  
93 of *C. auris* (MMC1 and MMC2, which are highly resistant and susceptible to  
94 fluconazole, respectively) (5) and *C. albicans*. Differences in size and sterol/protein  
95 ratios were observed. Using integrated multi-omics (proteomics, lipidomics and,  
96 transcriptomics) analysis we compared EVs and whole cells of *C. auris* and *C. albicans*  
97 and demonstrated significant compositional differences that could impact pathogenesis.  
98 Developing functional assays, we demonstrated that *C. auris* EVs influence adhesion to  
99 epithelial cells and activation of dendritic cells. Together our results show that *C. auris*  
100 produces EVs with a distinct composition in comparison with *C. albicans*, and *C. auris*  
101 EVs modulate host cell defense mechanisms.

102

### 103 **Methods**

104 **Cell lines:** Two well characterized *C. auris* clinical isolates (MMC1 and MMC2) were  
105 acquired from Montefiore Medical Center (NY, USA) (5). *C. albicans* strain (ATCC  
106 #90028), RAW 264.7 macrophages (ATTC #TIB-71) and HeLa cells (ATTC #CCL-2)  
107 were obtained from ATCC. Yeast cells were cultivated in YPD broth and seeded onto  
108 Sabouraud agar plates. For each experiment, colonies were inoculated in Sabouraud  
109 broth for 24 h at 30 °C before use. RAW 264.7 and HeLa cell lines were cultivated up to  
110 the 10<sup>th</sup> passage in DMEM supplemented with 10% FBS and 1% non-essential amino  
111 acids.

112 **EVs isolation:** One colony of each strain of *C. auris* or *C. albicans* was inoculated in 10  
113 mL of Sabouraud broth for 24 h at 30 °C, and then expanded in 200 mL of fresh  
114 medium. After an additional 24 h at 37 °C, the cells were centrifuged. The supernatant  
115 was filtered and concentrated 40 fold using an Amicon system with a 100-KDa  
116 molecular weight cutoff membrane. The concentrate was centrifuged twice at 150.000 x  
117 g at 4 °C for 1 hour, with a PBS washing step between each centrifugation step. The EV  
118 pellets were suspended in filtered PBS for most of the experiments, and in 50 mM  
119 ammonium bicarbonate for proteomic and lipidomic analyses.

120 **Transmission Electron Microscopy:** EVs pellets were fixed in 2.5% glutaraldehyde  
121 and 3 mM MgCl<sub>2</sub> in 0.1 M sodium cacodylate buffer, pH 7.2 overnight at 4 °C. Samples  
122 were then rinsed with buffer and post-fixed in 0.8% potassium ferrocyanide reduced 1%  
123 osmium tetroxide in the buffer for 1 h on ice in the dark. After a 0.1 M sodium  
124 cacodylate buffer rinse, the samples were incubated at 4 °C overnight in the same  
125 buffer. Samples were rinsed with 0.1 M maleate buffer, *en bloc* stained with 2% uranyl  
126 acetate (0.22 µm filtered, 1 h, dark) in 0.1 M maleate, dehydrated in a graded series of  
127 ethanol and embedded in Eponate 12 (Ted PElla) resin. Samples were polymerized at  
128 37 °C for 2 days and at 60 °C overnight. Thin sections, 60 to 90 nm, were cut with a  
129 diamond knife on a Reichert-Jung Ultracut E ultramicrotome and picked up with formvar  
130 coated copper slot grids. Grids were stained with 2% uranyl acetate in 50% methanol,  
131 followed by lead citrate, and observed with a Phillips CM120 transmission electron  
132 microscope at 80 kV. Images were captured with an AMT XR80 high-resolution (16-bit)  
133 8 Mpixel camera.

134 **Protein and ergosterol quantification:** Protein and sterols were quantified using BCA  
135 Protein Assay (Thermo) and Amplex Red Cholesterol Assay (Thermo) kits, respectively.  
136 Both contents were expressed as a function of the number of yeast cells present in  
137 each culture at harvest time.

138 **Hydrodynamic size distribution of extracellular vesicles by Dynamic light**  
139 **scattering:** EVs were suspended in PBS and their hydrodynamic size distributions were  
140 measured in a BI-90 Plus Particle Size Analyzer (Brookhaven Instruments) at room  
141 temperature as described (30). Vesicle preparations were first centrifuged at 13,000  
142 rpm for 5 minutes to remove any larger particles and aggregates. One hundred  
143 microliters of sample were loaded into disposable cuvette (Eppendorf 952010077) and  
144 analyzed by DLS. The average size distribution was calculated from duplicates of ten  
145 individual measurements.

146 **Isolation and sequencing of extracellular vesicles RNAs:** The RNA molecules were  
147 isolated with the miRNeasy mini kit (Qiagen) according to the manufacturer's protocol,  
148 that enables the purification of molecules from 18 nt up to messenger RNAs. This  
149 allowed us to obtain not only the small RNA-enriched fractions but also molecules  
150 longer than >200 nt. The RNA profile was assessed in an Agilent 2100 Bioanalyzer  
151 (Agilent Technologies). The purified RNA, from three independent biological replicates,  
152 was used for RNA-seq library construction using TruSeq small RNA kit (Illumina)  
153 according to the manufacturer's recommendations with a slight modification. During the  
154 acrylamide gel size selection, we excised the band ranging from 18 nt to >200 nt in  
155 length. The sequencing was performed with the Illumina HiSeq 2500 platform, TruSeq  
156 SBS Kit v3-HS 50 cycles kit (Illumina).

157 ***In silico* data analysis:** The RNA-seq analysis was performed with CLC Genomics  
158 Workbench© software version 20. The *C. auris* B8441 genome used for mapping was  
159 obtained from the NCBI database (GCA\_002759435.2). The alignment was performed  
160 as follows: additional 100-base upstream and downstream sequences; 10 minimum  
161 number of reads; 2 maximum number of mismatches; -2 nonspecific match limit, and  
162 minimum fraction length of 0.8 for the RNA mapping. The minimum reads similarity  
163 mapped on the reference genome was 80%. Only uniquely mapped reads were  
164 considered in the analysis. The libraries were normalized per million and the expression  
165 values for the transcripts were registered in TPM (Transcripts per Million). For the  
166 ncRNA the database used was the ncRNA from the *Candida* genome database:  
167 *C\_auris\_B8441\_version\_sXX-mYY-rZZ\_other\_features\_no\_introns.fasta.gz*. For the  
168 mRNA identification in the EVs, we combined the differential expression with reads  
169 coverage, so we performed the map reads to reference (*C\_auris\_B8441\_version\_s01-*  
170 *m01-r10\_genomic* and *C\_auris\_B8441\_version\_s01-m01-*  
171 *r10\_other\_features\_plus\_intergenic*) using the following parameters: No masking,  
172 match score (1), mismatch cost (2), linear insertion cost (3), deletion cost (3), length  
173 fraction (0.6), similarity fraction (0.8) and global alignment. To consider the full-length  
174 mRNAs we selected those with expression value (TPM) higher than 100 and also 5x  
175 transcript coverage. Gene Ontology analysis was performed using the DAVID  
176 annotation tool (31).

177 **Lipidomics and proteomics analyses of extracellular vesicles:** Sample processing  
178 and analysis were carried out as described (32, 33). Briefly, samples were submitted to  
179 simultaneous Metabolite, Protein and Lipid Extraction (MPLEX) (34). Extracted lipids

180 were dried in a vacuum centrifuge and dissolved in methanol before analysis by liquid  
181 chromatography-tandem mass spectrometry (LC-MS/MS) on a Velos Orbitrap mass  
182 spectrometer (Thermo Fisher). Lipid species were identified and manually inspected for  
183 validation based on head group and fatty acyl chain fragments using LIQUID (35). The  
184 intensities of each lipid species were extracted using MZmine 2.0 (36).

185 Proteins were dissolved in 100  $\mu$ l of 50 mM NH<sub>4</sub>HCO<sub>3</sub> containing 5 mM dithiothreitol  
186 and 8 M urea, and incubated for 15 minutes at 37 °C. Reduced thiol groups were  
187 alkylated with a final concentration of 10 mM iodoacetamide (from a 400 mM stock  
188 solution) incubated for 30 at room temperature. The reaction was quenched by adding  
189 500 mM dithiothreitol to a final concentration of 20 mM. Samples were diluted 8 fold with  
190 50 mM NH<sub>4</sub>HCO<sub>3</sub> containing 1 mM CaCl<sub>2</sub>, and digested with overnight at 37 °C with 2  
191  $\mu$ g sequencing-grade trypsin (Promega). Samples were desalted with solid-phase  
192 extraction C18 spin columns (Ultramicrospin columns, C18, 3- to 30- $\mu$ g capacity; Nest  
193 Group), as previously described (Ref:

194 <https://journals.asm.org/doi/epub/10.1128/mSphere.00085-15>).

195 Resulting peptides were dissolved in water and loaded into a C18 trap column (4 cm by  
196 100  $\mu$ m inner diameter [ID], packed in-house with 5  $\mu$ m C18; Jupiter). Chromatography  
197 was carried out on a capillary column (70 cm x 75  $\mu$ m ID packed with C18, 3- $\mu$ m  
198 particles) using a gradient of acetonitrile (mobile phase B) in water (mobile phase A),  
199 both supplemented with 0.1% formic acid. The elution was carried out at 300 nL/min  
200 with the following gradient: 19 min, 8% B; 60 min, 12% B; 155 min, 35% B; 203 min,  
201 60% B; 210 min, 75% B; 215 min, 95% B; 220 min, 95% B. Eluting samples were  
202 analyzed online with a Q-Exactive Plus mass spectrometer (Thermo Fisher Scientific).

203 Full scan spectra were collected in a window of 400 to 2,000 m/z with a resolution of  
204 70,000 at m/z 400. The 12 most intense parent ions were submitted to high-energy  
205 collision dissociation (32% normalized collision energy) at a resolution of 17,500.  
206 Dynamic exclusion was set to fragment each parent ion once and excluding them for 45  
207 sec.

208 Peptides were identified using MaxQuant (v.1.5.5.1) (37) by searching against the *C.*  
209 *albicans* SC5314 and *C. auris* sequences from Uniprot Knowledge Base (downloaded  
210 December 6, 2017). Intensity-based absolute quantification (iBAQ) method was used for  
211 quantification (38). The iBAQ values for individual proteins were normalized against the  
212 total sum of all proteins, resulting in the relative protein copy number (percentage from  
213 total). *C. auris* and *C. albicans* proteins were considered orthologs with  $\geq 40\%$  amino  
214 acid sequence similarity (39). Heatmap and clustering were performed with  
215 MultiExperiment Viewer (MeV) (40) or R software and Complex Heatmap package (41).  
216 For calculating fold changes and plotting the heatmaps, missing values were filled with  
217 half of the minimum value of the dataset. Function-enrichment analysis was done with  
218 DAVID (42), using default parameters. Bubble graphs were plot using Minitab  
219 v.19.2020.1.

220 **Adhesion assay to epithelial monolayers:** HeLa cells were seeded on coverslips  
221 placed in 24-wells plates and incubated for 24 h at 37 °C. Cell monolayers were pre-  
222 incubated with *C. auris* or *C. albicans* EVs (10  $\mu$ g/mL of protein) for 1 h and challenged  
223 with respective yeasts (pre-stained with NHS-Rhodamine for 30 minutes at 30 °C under  
224 shaking) for 1 h in a ratio of 20 yeast cells per HeLa cell. NHS-Rhodamine staining does  
225 not change yeast cell growth rates or other cellular characteristics (data not shown).

226 After extensive washing with PBS to remove non-adherent yeast, the cells were fixed  
227 with formalin and mounted with mounting media containing DAPI. Images were taken  
228 using a fluorescence microscope (Zeiss Imager Z1) and the adhesion was measured by  
229 the ratio between NHS-Rhodamine-positive cells divided by DAPI-positive cells for each  
230 field, using ImageJ. At least 8 fields containing approximately 400 epithelial cells per  
231 field from each slide were counted.

232 **Analysis of bone marrow-derived dendritic cells (BMDC) activation by**  
233 **extracellular vesicles:** BMDC were differentiated as described (43). Briefly, bone  
234 marrow cells were isolated from male C57BL/6 mice (approved protocol #2014-0501) by  
235 flushing both tibias and femurs with RPMI supplemented with 10% of fetal bovine serum  
236 (FBS). Bone marrow cells were cultivated for 10 days at 37 °C in the presence of GM-  
237 CSF (Peprotech) (43). Cultures were fed with media containing GM-CSF at days 3, 6  
238 and 8. BMDC phenotype was evaluated on day 10 by the surface exposure of CD11c  
239 and MHCII. At day 10 of differentiation, BMDC were incubated with 1 and 10 µg/mL  
240 (protein) of EVs from *C. auris* and *C. albicans* for 24 h at 37 °C and 5% CO<sub>2</sub>. After this  
241 period, cytokines IL-6, IL-10, IL-12p70, TNF-α, and TGF-β were measured in the culture  
242 supernatants using ELISA. BMDC were labeled with antibodies (α-CD11c, α-MHCII, α-  
243 CD80 and, α-CD86) to evaluate their purity and activation state using flow cytometry.

244 **Modulation of effector functions of macrophages by extracellular vesicles:**  
245 **Phagocytosis** – RAW 264.7 macrophages were plated onto 96-well plates and  
246 incubated for 24 h at 37 °C. Cells were then incubated with EVs from *C. albicans* or *C.*  
247 *auris* (10 µg/mL of protein) for 1 h until challenge with the respective yeast cell at 1:2  
248 (macrophage : yeast) for 1 h. Plates were washed to remove extracellular yeast cells

249 and then lysed with sterile water for CFU analysis. **Killing** –Bone marrow cells were  
250 harvested from C57BL/6 mice as detailed above and incubated with RPMI medium  
251 containing 10% of fetal bovine serum and 20% of L929 supernatant at 37 °C. On the  
252 fourth day, new medium containing L929 supernatant was added to the culture. On the  
253 seventh day of cultures, the cells had matured to differentiated macrophages, confirmed  
254 by the expression of F4/80 and absence of LY6C. BMDM were plated in 96-well plates  
255 and incubated at 37 °C for 24 h. Cells were incubated with EVs for 4 h at 37 °C until the  
256 challenge with yeast cells at 10:1 (macrophage:yeast) for 24 h at 37 °C. Cells were  
257 lysed and the suspensions plated onto Sabouraud plates for CFU counting.

258 **Statistical analyses:** All experiments were performed at least 3 independent times,  
259 unless stated otherwise. Data sets were analyzed using One-way ANOVA, and Dunnett  
260 multi comparison post-test using GraphPad Prism 8. All  $p$  values lower than 0.05 were  
261 considered significant.


262

## 263 **Results**

### 264 **Morphological characterization of *C. auris* extracellular vesicles**

265 EVs were isolated from the supernatant of *C. albicans* and *C. auris* cultures and then  
266 analyzed by transmission electron microscopy (TEM). As reported previously, EVs from  
267 *C. albicans* are round and bilayered particles (Figure 1A) (9). Similar results were  
268 observed for EVs from both *C. auris* isolates (Figure 1B and 1C), consistent with the  
269 reported morphology of other fungal EVs (7, 9, 12, 16, 20, 23, 25, 44). EVs were also  
270 analyzed by dynamic light scattering (DLS) to evaluate their global size. The size of EVs

271 isolated from *C. albicans* and *C. auris* MMC2 were very similar, ranging from 50 and 70  
272 nm and the second population between 170-250 nm (Figure 1A and 1C). *C. auris*  
273 MMC1 produced EVs of larger hydrodynamic size, ranging from 100 to 150 and the  
274 second population between 280 and 370 nm (Figure 1B).




275

276 **Figure 1. *C. auris* releases EVs.** Transmission electron micrographs and dynamic light  
277 scattering measurements of EVs from *C. albicans* (A) and *C. auris* isolates MMC1 (B)  
278 and MMC2 (C). Two independent EVs isolations were analyzed by both methods with  
279 similar results. The figure shows representative results of each analysis. Scale bars =  
280 100 nm

281

282 **Protein and ergosterol content of *C. auris* extracellular vesicles**

283 The amount of protein (Fig. 2A) and ergosterol (Fig. 2B) were determined and  
 284 normalized by the number of yeast cells in culture at the EV harvest time. Both *C. auris*  
 285 strains secreted similar amounts of protein in EVs, but the amounts were 3-4 times  
 286 lower compared to *C. albicans*. Likewise, the amounts of EVs ergosterol was 3-6 times  
 287 lower in *C. auris* strains than in *C. albicans*. *C. auris* MMC2 strain EVs had the lowest  
 288 amount of ergosterol, being 3 times lower compared to MMC1 (Figure 2B). As  
 289 ergosterol is a ubiquitous molecule present in EVs membranes, we normalized the  
 290 protein content by the amount of ergosterol in each strain as a way to measure possible  
 291 differential protein loads among isolates. MMC2 had a higher protein/ergosterol ratio  
 292 than either MMC1 or *C. albicans*.




293  
 294 **Figure 2. Protein and sterol content in *C. auris* and *C. albicans* extracellular  
 295 vesicles (EVs).** Protein (A) and sterol (B) concentrations were measured in EVs  
 296 suspensions from *C. auris* and *C. albicans* and normalized by the number of cells  
 297 present in the fungal cultures at the harvest time. (C) Protein to ergosterol concentration  
 298 ratios. All graphs represent means and standard error of the mean, relative to 4  
 299 independent EVs isolations. \*p ≤ 0.05; \*\*p ≤ 0.01 by One-way ANOVA followed by  
 300 Tukey's multiple comparison test.

301

302 **RNA content of *C. auris* extracellular vesicles**

303 We performed next-generation sequencing from both MMC1 and MMC2 EVs to  
304 investigate their RNA profiles, and compared against *C. albicans* EV-RNA. The analysis  
305 was performed applying a minimum of 40% nucleotide similarities between the  
306 orthologues. The first observation is that the RNA composition between MMC1 and  
307 MMC2 are very similar and most of the molecules identified in *C. auris* EVs were  
308 ncRNAs. The most represented ncRNA in *C. auris* in both strains are fragments of  
309 tRNAs (Table S1, Figure 3A). In *C. albicans* the tRNAs are also the most represented  
310 ncRNAs, and the snoRNAs are the second class of ncRNA in EVs, and this enrichment  
311 is not observed in *C. auris* (Figure 3B). For the tRNA fragments there was an  
312 enrichment for the 3' or 5' end of the tRNAs however no enrichment in the central  
313 portion of the tRNA was observed (Figure S1). Due to the library preparation, in the size  
314 selection step we cut the fragments related not only to the small fraction but also longer  
315 molecules, allowing the isolation of mRNAs as well. The RNA-seq analysis led to the  
316 identification of 57 mRNAs in *C. auris* and 32 in *C. albicans*. The top 10 most abundant  
317 transcripts from each species are summarized in Table 1 and all the mRNAs are listed  
318 in the Table S2. The transcript antisense to ribosomal RNA, Tar1 was the most enriched  
319 in *C. albicans* EVs, followed by the mRNA coding cell division control protein 42  
320 homolog and other transcripts related to cell cycle (Table S2). For *C. auris* the enriched  
321 transcripts were peptidyl-prolyl cis-trans isomerase, rapamycin-binding protein,  
322 translation elongation factor 1 subunit beta, E3 ubiquitin-activating protein and MFS  
323 family membrane transporter (Table S2). To validate the presence of full-length mRNAs

324 we selected only transcripts with reads coverage greater than 10x. It is possible to  
 325 observe that we obtained reads mapping along the entire transcript, as for example, the  
 326 Tar1 mRNA (Figure S2). In addition, it is also possible to observe that the transcript is  
 327 enriched only in *C. albicans*, no reads are mapping the Tar1 transcript in *C. auris* MMC1  
 328 and MMC2 strains (Figure S2). Overall, our results showed that *C. auris* EV carry RNA,  
 329 as demonstrated for other fungi (45-47).



330

331 **Figure 3. EV from *C. auris* carry RNA. (A)** Comparison between ncRNAs enriched in  
 332 the *C. auris* EVs compared *C. albicans* EVs. (B) Heatmap representing the differentially  
 333 expressed ncRNA in the EVs comparing *C. auris* and *C. albicans* (FDR <1% and fold  
 334 change FC 10-fold). The expression levels are visualized using a gradient color


335 scheme, blue – high expression level, red – low expression level and the values  
336 represent the logFC.

337

338 **Proteomics analysis of extracellular vesicles**

339 We performed a liquid chromatography tandem mass spectrometry (LC-MS/MS)-based  
340 proteomic analysis to compare the protein profiles across both species. We utilized a  
341 threshold of 40% of homology at amino acid level between the species to consider them  
342 homologs (Table S3). The divergent peptide sequences prevent to directly compare  
343 peak areas between the two species since the sequence divergency might cause the  
344 peptides to not have same signal response in the mass spectrometer. Therefore, we  
345 calculated the relative copy number of proteins per sample (% from total) to compare  
346 between the two species. In addition to compare the EV proteins from both species, we  
347 also compared the EVs data with the proteomics analysis of whole cells (39), which  
348 were prepared and run in parallel. We observed striking differences between the whole  
349 cells and EVs for each of the 3 strains (Figure 4A). We performed hierarchical clustering  
350 to separate groups of proteins based on their abundance profile. Cluster 1, which  
351 contains proteins commonly enriched in EVs from *C. auris* and *C. albicans* compared to  
352 their respective cells, were enriched in proteins from starch and sucrose metabolism,  
353 protein processing in the endoplasmic reticulum, MAP kinases, and amino sugar and  
354 nucleotide sugar metabolism (Figure 4A). *C. albicans*, but not *C. auris* EVs, were  
355 enriched in abundant cellular proteins, such as ribosomal proteins and proteins from the  
356 central carbon and amino acid metabolism (Cluster 2 in Figure 4A). EVs from both  
357 species were depleted of proteins from functions such as ribosomal biogenesis,

358 proteasome, DNA replication, RNA degradation, and sterol biosynthesis (Clusters 3-5 in  
 359 Figure 4A). Within the ten most abundant proteins in whole cells, only enolase 1 and  
 360 pyruvate decarboxylase had high amounts in EVs (*C. albicans*) (Figure 4B). None of the  
 361 top 10 most abundant whole-cell proteins were abundant in *C. auris* EVs (Figure 4B).  
 362 On the other hand, the top 10 most abundant EVs proteins were present only in small  
 363 amounts in whole cells (Figure 4B), suggesting a highly selective process to upload  
 364 proteins into EVs.



365


366 **Figure 4. Comparative proteomic analysis of extracellular vesicles and whole**  
 367 **cells from *C. albicans* and *C. auris*.** Proteomic data of whole cells and extracellular  
 368 vesicles were submitted to intensity-based absolute quantification (iBAQ) and converted

369 to relative copy numbers before comparing across different samples. (A) Heatmaps and  
370 hierarchical clustering were performed with MeV and function enrichment of each  
371 cluster was performed with DAVID. (B) Profiles of the 10 most abundant whole-cell  
372 (WC) and extracellular vesicles (EVs) proteins. Cell samples correspond to three  
373 independent cultures and EVs samples correspond to 4 independent EVs isolations.

374

375 Among all the proteins detected in EVs, 393 were considered differentially abundant  
376 when comparing *C. auris* (both strains) with *C. albicans*. We performed hierarquical  
377 clusters of the differential abundant proteins, followed by functional-enrichment analysis.  
378 To provide information on the number of proteins in each enriched, we showed the  
379 pathway enrichment results as bubble graphs. In this layout, the enrichment fold  
380 change and p-values are plot in X and Y axes, respectively, while the circle sizes  
381 present the number of proteins and the colors, the clusters they belong to. The number  
382 of differentially abundant proteins corresponded to 33% of the detected proteins, so the  
383 abundance of the remaining 66% was similar among the species. The heatmap in figure  
384 5A shows all the major differentially abundant EVs proteins among the evaluated  
385 organisms. The heatmap was divided into three clusters based on differences of protein  
386 abundance between EVs from *C. auris* and *C. albicans*. Out of the 393 proteins on the  
387 heatmap, 42 proteins (~10%) were more abundant in *C. auris* than *C. albicans* (Cluster  
388 2, Figure 5). This group of proteins was enriched in proteins from the starch and  
389 sucrose metabolism and protein processing in the endoplasmic reticulum (Figure 5B).  
390 As mentioned above, *C. albicans* EVs had higher amounts of metabolic proteins  
391 (Cluster 3, Figure 5A-B). *C. albicans* EVs had higher amounts of TCA cycle proteins

392 (figure 5B), which is the opposite of what was found in whole cells (39). This result  
 393 further supports the presence of a selective mechanism for sorting proteins into the  
 394 EVs.




395  
 396 **Figure 5. Proteomics analysis of EVs from *C. auris*.** EVs from both *Candida* species  
 397 were submitted to protein extraction and analysis. The heatmap (A) shows the  
 398 abundance of proteins differentially abundant in EVs from both species of *Candida*. The  
 399 heatmap was clustered using the hierarchical method. (B) Function-enrichment analysis  
 400 of different clusters of proteins from panel A. The enrichment of pathways was done  
 401 with DAVID. The graph represents the relationship between p-values and fold  
 402 enrichment. The colors of the circles represent the different clusters they are enriched  
 403 in, while the size, the number of proteins from each pathway. EVs samples correspond  
 404 to 4 independent EVs isolations.

405

406 **Lipidomics analysis of extracellular vesicles**

407 We performed a lipidomics analysis to compare the lipid profile of *C. auris* and *C.*  
408 *albicans* EVs (Figure 6A-B). All detected species of diacylglycerols (DG) and  
409 triacylglycerols (TG) were more abundant in EVs from *C. albicans*, whereas the majority  
410 of glycerophospholipids were enriched in the *C. auris* isolates, including  
411 phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG)  
412 and phosphatidylserine (PS) species (Figure 6A). Conversely, phosphatidic acid (PA)  
413 and phosphatidylinositol (PI) species were more abundant in *C. albicans* (Figure 6A).  
414 The pattern of sphingolipids was also distinct when the *Candida* EVs were compared.  
415 Two major species of conserved hexosylceramides (HexCer) were found in EVs from *C.*  
416 *albicans* and *C. auris* (Figure 6B), corresponding to the same distribution characterized  
417 in their respective yeast extracts recently reported by our group (5). Consistent with  
418 that, HexCer species bearing Cer(d18:1/24:0(2OH)) and Cer(d20:0/18:0) were more  
419 abundant in *C. albicans* EVs. Non-acylated sphingoid bases sphinganine Cer(d18:0/0:0)  
420 and sphingosine Cer(d18:1/0:0) were more abundant in *C. auris* MMC2 (Table S4). We  
421 also found unusual free ceramide species with acetate as the acyl group (Figure 6C),  
422 known as C2-ceramides, which were more abundant in *C. auris* MMC1. Remarkably,  
423 Cer(d18:1/2:0) comprises 7.9% of the mass spectrometry signal for all identified lipids in  
424 the positive ion mode analysis of *C. auris* MMC1 EVs, but only 0.6% and 0.2% of the *C.*  
425 *auris* MMC2 and *C. albicans* EVs, respectively (Figure 6C). We compared the relative  
426 intensities of Cer(d18:1/2:0) to the whole cell data from our recent publication(5). We  
427 found an enrichment of 25, 67, and 109 folds of this lipid species in EVs compared to  
428 the whole cells in *C. auris* MMC1, *C. auris* MMC2 and *C. albicans*, respectively.

429 Recently, we reported that *C. auris* had higher expression of a variety of  
 430 phospholipases compared to *C. albicans* (5), therefore, we took a closer look at their  
 431 products, lysophospholipids(48). *C. auris* MMC2 EVs had a consistent higher  
 432 abundance of lysophosphatidylcholine (LPC) and lysophosphatidylethanolamine (LPE)  
 433 species compared to *C. auris* MMC1 and *C. albicans* (Figure 6D).  
 434 Lysophosphatidylglycerol (LPG) species, being PG(18:0/0:0), PG(18:1/0:0), and  
 435 PG(18:2/0:0) more abundant in *C. auris* MMC2, *C. albicans* and *C. auris* MMC1,  
 436 respectively (Figure 6D).  
 437 Fatty acids (FA) chains were detected in all organisms and ranged in size from 14 to 24  
 438 carbons, and arachidonic acid was detected, esterified to phosphatidylethanolamine  
 439 (PE(18:2/20:4)), consistently in both *C. auris* isolates. Arachidonic acid was not  
 440 abundant in the evaluated strain of *C. albicans* in the tested conditions (Table S4).



441  
 442 **Figure 6. Lipid profile of *C. auris* and *C. albicans* EVs.** Vesicles from both *Candida*  
 443 species were submitted to lipid extraction and analysis by LC-MS/MS. (A) Heatmap of

444 the relative abundances of EVs lipids from both *Candida* species. (B) Relative intensity  
445 of hexosylceramides. (C) Relative intensity of Cer(d18:1/2:0) was compared between  
446 EVs and yeast cells among all *Candida* species. (D) Relative abundance of  
447 lysophospholipids In *C. auris* and *C. albicans* EVs. Data were analyzed by one-way  
448 ANOVA followed by Tukey's multiple comparison test. Different letters among bars  
449 represent  $p < 0.05$ . EVs samples correspond to 4 independent EVs isolations.


450 Abbreviations: Cer, ceramide; DG, diacylglycerol; PA, phosphatidic acid; PC,  
451 phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI,  
452 phosphatidylinositol; PS, phosphatidylserine; TG, triacylglycerol.

453

#### 454 **Effects of extracellular vesicles on the yeast adhesion to epithelial cells**


455 Adhesion to epithelial surfaces is an important feature displayed by pathogenic species  
456 of *Candida* as an early stage of colonization of host tissues (49-52). We evaluated  
457 whether *C. albicans* or *C. auris* EVs had an impact on the adhesion of *C. auris* or *C.*  
458 *albicans* to HeLa epithelial cells monolayers. Pre-incubation of HeLa cells with *C. auris*  
459 MMC1 EVs increased the adhesion of this yeast. The same was not seen for MMC2 or  
460 for *C. albicans*, as the pre-treatment with their EVs did not affect the adhesion of yeast  
461 to HeLa cells (Figure 7). This result shows how EVs from different strains of the same  
462 species can induce distinct host cells phenotypes.

A



463

B




464 **Figure 7. The effect of extracellular vesicle (EVs) pretreatment on the adhesion of**  
 465 **yeast cells to epithelial monolayers.** HeLa cells were pre-treated, or not, with EVs (10  
 466 µg/mL of protein) for 1 h before challenging with the respective yeast cells. After  
 467 incubating for 1 h, monolayers were washed, and slides were analyzed under a  
 468 fluorescence microscope (see Methods for details). (A) Quantification of adhering yeast  
 469 cells. (B) Fluorescence image of *C. auris* MMC1 adhesion to HeLa cells. Nuclei were  
 470 stained with DAPI (blue), whereas the yeasts were stained with NHS-Rhodamine (red).  
 471 The graph shows average and standard errors relative to 2 independent experiments  
 472 made with distinct EV preparations. \* $p < 0.05$  by one-way ANOVA followed by Dunnet  
 473 test.

474

475 **Effect of extracellular vesicles on phagocytosis and killing by macrophages**

476 EVs from certain fungi can affect the way yeast cells are internalized and killed by  
 477 macrophages (8, 13-16, 53). We tested whether EVs from *C. auris* or *C. albicans* would  
 478 be able to modulate the uptake or clearance of yeast cells by macrophages. The  
 479 incubation with EVs from either *C. albicans* or *C. auris* had no significant effect on the  
 480 phagocytosis of yeast cells by macrophages (Figure 8A). However, whereas EVs pre-  
 481 incubation enhanced macrophages' ability to kill *C. albicans*, EVs from *C. auris* MMC2  
 482 but not MMC1, enhanced yeast cell proliferation within the macrophages (Figure 8B).  
 483 This points to differing roles for EVs among species regarding some of the effector  
 484 functions of macrophages.



485


486 **Figure 8. Phagocytosis and killing by macrophages.** (A) RAW 264.7 macrophages  
 487 were incubated with EVs for 1 h and then challenged with yeast cells in the ratio of 1:2  
 488 (macrophage:yeast) for 1 h. After this period, extracellular yeast cells were washed off  
 489 and macrophages were lysed and plated onto Sabouraud for CFU counting. (B) Bone  
 490 marrow-derived macrophages were incubated with EVs for 4 h and then challenged with  
 491 yeast in the ratio of 10:1 (macrophages:yeast) for 24 h. The macrophages were then  
 492 lysed and plated onto Sabouraud for CFU counting. Graphs show averages and

493 standard error on the mean for 4 independent experiments made with distinct EV  
494 preparations. \* $p < 0.05$  by paired T-test.

495

496 **Activation of dendritic cells by extracellular vesicles**

497 We investigated the ability of *C. auris* to regulate dendritic cells by measuring 3  
498 important signals for antigen presentation and activation of T cells, MHC-II, co-  
499 stimulatory molecules (CD80 and CD86), and cytokines (54). BMDC were incubated for  
500 24 h with *C. auris* or *C. albicans* EVs, and MHC-II and co-stimulatory molecules were  
501 measured by FACS, whereas cytokines were assayed by ELISA. We observed an  
502 increase of surface markers associated with BMDC activation, which was similar to the  
503 one induced by LPS. Despite that, MMC2 EVs induced a lower response, and all tested  
504 EVs concentrations from *C. auris* and *C. albicans* were able to increase, in a dose-  
505 dependent manner, the expression of MHCII, CD80, and CD86 on BMDC (Figure 9A-  
506 C). BMDC treated with EVs from both *Candida* species did not produce IL-10, IL-12 or  
507 TNF- $\alpha$ . However, BMDC stimulated with EVs from *C. auris* produced IL-6 similarly to *C.*  
508 *albicans* (Figure 9D). In addition, inhibition of the basal production of TGF- $\beta$  by BMDC  
509 was detected after the incubation with EVs from *C. auris* MMC1 and *C. albicans* (Figure  
510 9E).



511

512 **Figure 9. Activation of BMDC by *C. auris* extracellular vesicles (EVs).** BMDC were  
 513 incubated, or not with EVs from *C. albicans* and *C. auris* for 24 h and then analyzed by  
 514 flow cytometry (A-C) for the expression of MHC-II (A), CD80 (B) and CD86, or ELISA  
 515 (7D and 7E), for the production of IL-6 (D) and TGF-β (E). Graphs show mean and  
 516 standard error for 3 independent experiments made with distinct EV preparations. \* = p  
 517 < 0.05 by ANOVA followed by Tukey.

518

519 **Discussion**

520 The literature reports two distinct populations of EVs from other species of *Candida*, a  
 521 smaller one ranging usually from 50-70 nm, and a larger group between 100 and 800  
 522 nm (9, 25, 44). We found that *C. auris* releases EVs encompassed by lipid bilayers with  
 523 size and shape consistent with those from other species. TEM showed that, as opposed

524 to some species such as *Histoplasma capsulatum* (25) and *Cryptococcus neoformans*  
525 (*C. auris* EVs lack electron-dense areas associated with pigmentation. The total  
526 content of protein and ergosterol in EVs suspensions was higher in *C. albicans* than in  
527 either *C. auris* strain when normalized by the number of producing cells. The ratio  
528 between proteins and sterol excludes the number of cells from the analysis and *C. auris*  
529 MMC2 had a ratio higher than *C. albicans* or *C. auris* MMC1.

530 EVs RNAs have been characterized in *C. neoformans*, *S. cerevisiae*, *P. brasiliensis*, *H.*  
531 *capsulatum* and *C. albicans* (45, 46). The most abundant transcripts of EVs from *C.*  
532 *auris* MMC1 and MMC2 were associated with general metabolism, ribonuclease, and  
533 ubiquitin activities or from uncharacterized genes. EVs mRNAs of *C. albicans* and *C.*  
534 *auris* share common biological processes, such as cellular response to stress and  
535 filamentous growth, indicating a conserved sorting mechanism (45). In other  
536 eukaryotes, EVs mRNAs can be translated into the recipient cell (55), although this  
537 should be experimentally addressed for fungal EVs. The most abundant ncRNAs in EVs  
538 from *C. auris* MMC1 and MMC2 were tRNAs and their fragments, similar to previously  
539 described for *C. albicans* (~60%). These fragments of tRNA have been described in  
540 EVs of diverse organisms, from unicellular parasites to human cells (56-58). In T  
541 lymphocytes-derived EVs, the most abundant class of RNA characterized is tRNA  
542 fragments, comprising 45% of all RNA identified in the EVs compared to the cell  
543 content, and these fragments act by repressing immune activation in T cells (59).

544 The EVs proteomic profile was strikingly different from the cells they are derived from.  
545 Whereas *C. auris* EVs were enriched in proteins from the starch and sucrose  
546 metabolism and protein processing in the endoplasmic reticulum, *C. albicans* EVs had

547 higher amounts of proteins from the central carbon metabolism, ribosomes, and amino  
548 acid metabolism. We have previously shown that TCA cycle proteins were more  
549 abundant in *C. auris* yeast cells than *C. albicans* (39), but we are now showing an  
550 opposite phenotype in EVs, suggesting a selective sorting that could help control the  
551 intracellular levels of specific metabolic enzymes. These differences suggest that the  
552 EVs from *C. albicans* and *C. auris* are involved with distinct metabolic adaptations. In  
553 terms of lipid composition, the relative abundance of lipids involved with energy storage,  
554 as triacyl- and diacylglycerols (TG and DG), is remarkably higher in EVs from *C.*  
555 *albicans*, when compared to the *C. auris* ones, reflecting the pattern found in their  
556 originating yeast cells (5). The relative abundance of structural glycerophospholipids is  
557 consistently higher in EVs from both isolates of *C. auris*, also reflecting the lipid profile  
558 of their generating yeast cells (5). Although for some cases the lipid profile from *C. auris*  
559 EVs resembled the yeast cell one, some lipids from the yeast cells were not present in  
560 EVs, such as cardiolipins, which are mitochondrial markers. The amount of HexCer  
561 correlated with the distribution in their respective cells, as previously showed by our  
562 group (5). Considered initially as membrane structural components, HexCer were  
563 described as virulence regulators in *C. albicans* and *C. neoformans* (60, 61). Their role  
564 in EVs could be linked to membrane and lipid raft stability (62). However, recently, Xisto  
565 and colleagues demonstrated that purified HexCer produced by the opportunistic fungus  
566 *Lomentospora prolificans* induced an oxidative burst by and increased the antifungal  
567 activity of macrophages (63).  
568 To our knowledge, our findings report the first time that a C2-ceramide derivative has  
569 been found in fungal EVs. In mammalian models, C2-ceramide has biological properties

570 such as antitumoral activity inducing apoptosis and arresting cell cycle (64, 65). The  
571 relative abundance of lysophospholipids was considerably higher in EVs from *C. auris*  
572 than *C. albicans*, particularly in EVs from MMC2. This data suggests an intense activity  
573 of lipid catabolic enzymes in *C. auris*, such as phospholipases. Some lysophospholipids  
574 are biologically active on leukocytes, for instance, LPC released by apoptotic  
575 neutrophils recruit monocytes from the bloodstream to promote clearance of apoptotic  
576 bodies from tissues (66). Immunomodulatory properties of LPC were demonstrated for  
577 other infection models and LPC could act as a virulence factor in *C. auris* infections (67,  
578 68).

579 To examine the potential biological effects of EVs upon host cells and to compare  
580 biological activities between species, we used amounts of EVs based on protein  
581 concentration in the same range as used in other reports for host-pathogen studies (8,  
582 9, 16, 17). Within this concentration range, EVs from other pathogenic fungi, were  
583 proven to be biologically active in distinct models. Adhesion of yeast cells to epithelial  
584 surfaces is an important mechanism of disease as an initial step for further tissue  
585 damage and colonization of distinct sites in the host, including the bloodstream (52). *C.*  
586 *albicans* can interact with surface adhesion molecules on epithelial cells (50, 51), so we  
587 investigated whether EVs from both *Candida* species were able to modulate the  
588 adhesion of yeast to epithelial monolayers *in vitro*. Although the tested strains were able  
589 to adhere to the epithelial monolayer, a significant increase in adhesion was observed  
590 when EVs from *C. auris* MMC1 were added to the monolayer. Notably, *C. neoformans*  
591 EVs fuse with brain microvascular endothelial cells, changing their permeability (22).  
592 Since in our studies the epithelial cells were incubated with EVs prior to the challenge

593 with yeast cells, it is possible that fusion with the epithelial cells could modify their  
594 permeability and/or modulate the exposure of adhesion molecules, although further  
595 experimentation is needed to address this hypothesis. Molecules involved with the  
596 adhesion of *C. albicans* to epithelial cells have been described, such as *C. albicans*  
597 ALs3p and Eap1p, and are potential players in the increase of adhesion induced by EVs  
598 (69).

599 Fungal EVs can induce the activation of phagocytes, increasing phagocytosis, cytokine  
600 production, and antigen presentation (8-10, 17). EVs isolated from both *C. auris* strains  
601 did not modulate the uptake of yeast cells by macrophage cell lines as RAW, but EVs  
602 from *C. auris* MMC2 inhibited the killing of yeast cells by BMDM. EVs from *C. albicans*  
603 increased the killing of yeast cells by BMDM. EVs from other pathogenic fungi can  
604 modulate phagocytosis and/or killing by macrophages, but our data shows that EVs  
605 from only one of the *C. auris* isolates (MMC2) could inhibit the killing of the pathogen by  
606 macrophages. This data suggests that EVs from the same species could promote  
607 distinct changes in host cells. EVs from *C. albicans* followed the pattern played by most  
608 fungal EVs, as they induced killing (8, 10, 14-16, 53). The incubation with EVs  
609 stimulated BMDC to express important signals responsible for CD4+ T cells activation  
610 such as MHCII, CD80 and CD86. The secretion of TNF- $\alpha$ , IL-10 and IL-12p70 by BMDC  
611 was not detected at biologically relevant levels. However, EVs from both *C. albicans*  
612 and *C. auris* induced the release of IL-6 by BMDC, while decreasing the basal  
613 production of TGF- $\beta$ . This suggests that EVs from *C. albicans* and *C. auris* MMC1  
614 induce an inflammatory response in BMDC. Apart from previously reported (9), TNF- $\alpha$ ,  
615 IL-10 and IL-12p70 were not produced by BMDC stimulated with EVs. Different strain of

616 *C. albicans* were used these studies, reinforcing the possibility that the biological activity  
617 of EVs could be strain specific.

618 In summary, our results show that the emerging pathogen *C. auris* produces EVs that  
619 are similar in size to other pathogenic fungi, but the content of these EVs distinctly  
620 differs from what is known for *C. albicans* and these differences could explain the  
621 phenotypic changes induced by these EVs in the cells from the host. In this regard, we  
622 note that *C. auris* is a new fungal pathogen that has been proposed to have emerged  
623 from the environment as a result of global warming (70). In contrast, *C. albicans* has an  
624 ancient association with human hosts. Thus, the similarities in structure and content  
625 between *C. auris* and *C. albicans* EVs probably reflect constraints common to fungal  
626 cells and their physiology, while the differences reflect species-specific variables and  
627 perhaps the result of differences in the time of adaptation to human hosts.

628

## 629 **Acknowledgements**

630 The Johns Hopkins University School of Medicine Microscope Facility. D.Z.M., J.D.N.  
631 and E.S.N. were supported by National Institute of Health-National Institute of Allergy  
632 and Infectious Diseases R21 AI124797. L.N. was supported by grants from the Brazilian  
633 agency Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grants  
634 311179/2017-7 and 408711/2017-7) and FAPERJ (E-26/202.809/2018). M.L.R. was  
635 supported by grants from the Brazilian Ministry of Health (grant number 440015/2018-  
636 9), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, grants  
637 405520/2018-2, and 301304/2017-3) and Fiocruz (grants PROEP-ICC 442186/2019-

638 3, VPPCB-007- FIO-18 and VPPIS-001-  
639 FIO18). M.L.R. also acknowledges support from the Instituto Nacional de Ciência e  
640 Tecnologia de Inovação em Doenças de Populações Negligenciadas (INCT-IDPN).  
641 A.C. was supported in part by NIH grants AI052733, AI15207 and HL059842. Parts of  
642 this work were performed in the Environmental Molecular Science Laboratory, a U.S.  
643 Department of Energy (DOE) national scientific user facility at PNNL in Richland, WA.

644

## 645 **References**

- 646 1. Snyder GM, Wright SB. 2019. The Epidemiology and Prevention of *Candida*  
647 *auris*. *Current Infectious Disease Reports* 21:19.
- 648 2. Li W, Hu Y. 2017. Assessment of Post-Vaccination Phagocytic Activation Using  
649 *Candida albicans* Killing Assays. *Methods Mol Biol* 1625:313-326.
- 650 3. Kean R, Ramage G. 2019. Combined Antifungal Resistance and Biofilm  
651 Tolerance: the Global Threat of *Candida auris*. *mSphere* 4.
- 652 4. Rhodes J, Fisher MC. 2019. Global epidemiology of emerging *Candida auris*.  
653 *Current Opinion in Microbiology* 52:84-89.
- 654 5. Zamith-Miranda D, Heyman HM, Cleare LG, Couvillion SP, Clair GC, Bredeweg  
655 EL, Gacser A, Nimrichter L, Nakayasu ES, Nosanchuk JD. 2019. Multi-omics  
656 Signature of *Candida auris*, an Emerging and Multidrug-Resistant Pathogen.  
657 *mSystems* 4:e00257-19.
- 658 6. Rodrigues ML, Godinho RMC, Zamith-Miranda D, Nimrichter L. 2015. Traveling  
659 into Outer Space: Unanswered Questions about Fungal Extracellular Vesicles.  
660 *PLOS Pathogens* 11:e1005240.
- 661 7. Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, Zaragoza O,  
662 Alvarez M, Nakouzi A, Feldmesser M, Casadevall A. 2007. Vesicular  
663 polysaccharide export in *Cryptococcus neoformans* is a eukaryotic solution to the  
664 problem of fungal trans-cell wall transport. *Eukaryot Cell* 6:48-59.
- 665 8. Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, Casadevall A, Rodrigues ML,  
666 Nimrichter L. 2010. Extracellular vesicles from *Cryptococcus neoformans*  
667 modulate macrophage functions. *Infect Immun* 78:1601-9.
- 668 9. Vargas G, Rocha JD, Oliveira DL, Albuquerque PC, Frases S, Santos SS,  
669 Nosanchuk JD, Gomes AM, Medeiros LC, Miranda K, Sobreira TJ, Nakayasu  
670 ES, Arigi EA, Casadevall A, Guimaraes AJ, Rodrigues ML, Freire-de-Lima CG,  
671 Almeida IC, Nimrichter L. 2015. Compositional and immunobiological analyses of  
672 extracellular vesicles released by *Candida albicans*. *Cell Microbiol* 17:389-407.

673 10. da Silva TA, Roque-Barreira MC, Casadevall A, Almeida F. 2016. Extracellular  
674 vesicles from *Paracoccidioides brasiliensis* induced M1 polarization in vitro. *Sci  
675 Rep* 6:35867.

676 11. Vargas G, Honorato L, Guimarães AJ, Rodrigues ML, Reis FCG, Vale AM, Ray  
677 A, Nosanchuk JD, Nimrichter L. Protective effect of fungal extracellular vesicles  
678 against murine candidiasis. *Cellular Microbiology* n/a:e13238.

679 12. Vallejo MC, Matsuo AL, Ganiko L, Medeiros LC, Miranda K, Silva LS, Freymuller-  
680 Haapalainen E, Sinigaglia-Coimbra R, Almeida IC, Puccia R. 2011. The  
681 pathogenic fungus *Paracoccidioides brasiliensis* exports extracellular vesicles  
682 containing highly immunogenic alpha-Galactosyl epitopes. *Eukaryot Cell* 10:343-  
683 51.

684 13. Almeida F, Wolf JM, da Silva TA, DeLeon-Rodriguez CM, Rezende CP, Pessoni  
685 AM, Fernandes FF, Silva-Rocha R, Martinez R, Rodrigues ML, Roque-Barreira  
686 MC, Casadevall A. 2017. Galectin-3 impacts *Cryptococcus neoformans* infection  
687 through direct antifungal effects. *Nat Commun* 8:1968.

688 14. Brauer VS, Pessoni AM, Bitencourt TA, de Paula RG, de Oliveira Rocha L,  
689 Goldman GH, Almeida F. 2020. Extracellular Vesicles from *Aspergillus flavus*  
690 Induce M1 Polarization *In Vitro*. *mSphere* 5:e00190-20.

691 15. Bitencourt TA, Rezende CP, Quaresmin NR, Moreno P, Hatanaka O, Rossi A,  
692 Martinez-Rossi NM, Almeida F. 2018. Extracellular Vesicles From the  
693 Dermatophyte *Trichophyton interdigitale* Modulate Macrophage and Keratinocyte  
694 Functions. *Frontiers in Immunology* 9: .

695 16. Souza JAM, Baltazar LdM, Carregal VM, Gouveia-Eufrasio L, de Oliveira AG,  
696 Dias WG, Rocha de Miranda K, Malavazi I, Santos DdA, Frézard FJG, de Souza  
697 DdG, Teixeira MM, Soriano FM. 2019. Characterization of *Aspergillus fumigatus*  
698 Extracellular Vesicles and Their Effects on Macrophages and Neutrophils  
699 Functions. *Frontiers in Microbiology* 10.

700 17. Baltazar LM, Zamith-Miranda D, Burnet MC, Choi H, Nimrichter L, Nakayasu ES,  
701 Nosanchuk JD. 2018. Concentration-dependent protein loading of extracellular  
702 vesicles released by *Histoplasma capsulatum* after antibody treatment and its  
703 modulatory action upon macrophages. *Scientific Reports* 8:8065.

704 18. Colombo AC, Rella A, Normile T, Joffe LS, Tavares PM, de SAGR, Frases S,  
705 Orner EP, Farnoud AM, Fries BC, Sheridan B, Nimrichter L, Rodrigues ML, Del  
706 Poeta M. 2019. *Cryptococcus neoformans* Glucuronoxylomannan and  
707 Sterylglucoside Are Required for Host Protection in an Animal Vaccination  
708 Model. *mBio* 10.

709 19. Brauer VS, Pessoni AM, Bitencourt TA, de Paula RG, de Oliveira Rocha L,  
710 Goldman GH, Almeida F. 2020. Extracellular Vesicles from *Aspergillus flavus*  
711 Induce M1 Polarization *In Vitro*. *mSphere* 5.

712 20. Gehrmann U, Qazi KR, Johansson C, Hultenby K, Karlsson M, Lundeberg L,  
713 Gabrielsson S, Scheynius A. 2011. Nanovesicles from *Malassezia sympodialis*  
714 and Host Exosomes Induce Cytokine Responses – Novel Mechanisms for Host-  
715 Microbe Interactions in Atopic Eczema. *PLOS ONE* 6:e21480.

716 21. Johansson HJ, Vallhov H, Holm T, Gehrmann U, Andersson A, Johansson C,  
717 Blom H, Carroni M, Lehtio J, Scheynius A. 2018. Extracellular nanovesicles

718 released from the commensal yeast *Malassezia sympodialis* are enriched in  
719 allergens and interact with cells in human skin. *Sci Rep* 8:9182.

720 22. Huang SH, Wu CH, Chang YC, Kwon-Chung KJ, Brown RJ, Jong A. 2012.  
721 *Cryptococcus neoformans*-derived microvesicles enhance the pathogenesis of  
722 fungal brain infection. *PLoS One* 7:e48570.

723 23. Ikeda MAK, de Almeida JRF, Jannuzzi GP, Cronemberger-Andrade A,  
724 Torrecilhas ACT, Moretti NS, da Cunha JPC, de Almeida SR, Ferreira KS. 2018.  
725 Extracellular Vesicles From *Sporothrix brasiliensis* Are an Important Virulence  
726 Factor That Induce an Increase in Fungal Burden in Experimental Sporotrichosis.  
727 *Frontiers in Microbiology* 9.

728 24. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida  
729 IC, Casadevall A. 2008. Extracellular vesicles produced by *Cryptococcus*  
730 *neoformans* contain protein components associated with virulence. *Eukaryot Cell*  
731 7:58-67.

732 25. Albuquerque PC, Nakayasu ES, Rodrigues ML, Frases S, Casadevall A,  
733 Zancope-Oliveira RM, Almeida IC, Nosanchuk JD. 2008. Vesicular transport in  
734 *Histoplasma capsulatum*: an effective mechanism for trans-cell wall transfer of  
735 proteins and lipids in ascomycetes. *Cell Microbiol* 10:1695-710.

736 26. Vallejo MC, Nakayasu ES, Matsuo AL, Sobreira TJ, Longo LV, Ganiko L,  
737 Almeida IC, Puccia R. 2012. Vesicle and vesicle-free extracellular proteome of  
738 *Paracoccidioides brasiliensis*: comparative analysis with other pathogenic fungi. *J*  
739 *Proteome Res* 11:1676-85.

740 27. Gil-Bona A, Llama-Palacios A, Parra CM, Vivanco F, Nombela C, Monteoliva L,  
741 Gil C. 2015. Proteomics unravels extracellular vesicles as carriers of classical  
742 cytoplasmic proteins in *Candida albicans*. *J Proteome Res* 14:142-53.

743 28. Matos Baltazar L, Nakayasu ES, Sobreira TJ, Choi H, Casadevall A, Nimrichter  
744 L, Nosanchuk JD. 2016. Antibody Binding Alters the Characteristics and  
745 Contents of Extracellular Vesicles Released by *Histoplasma capsulatum*.  
746 *mSphere* 1.

747 29. Zhao K, Bleackley M, Chisanga D, Gangoda L, Fonseka P, Liem M, Kalra H, Al  
748 Saffar H, Keerthikumar S, Ang C-S, Adda CG, Jiang L, Yap K, Poon IK, Lock P,  
749 Bulone V, Anderson M, Mathivanan S. 2019. Extracellular vesicles secreted by  
750 *Saccharomyces cerevisiae* are involved in cell wall remodelling. *Communications*  
751 *Biology* 2:305.

752 30. Eisenman HC, Frases S, Nicola AM, Rodrigues ML, Casadevall A. 2009. Vesicle-  
753 associated melanization in *Cryptococcus neoformans*. *Microbiology* 155:3860-7.

754 31. Huang DW, Sherman BT, Lempicki RA. 2009. Systematic and integrative  
755 analysis of large gene lists using DAVID bioinformatics resources. *Nature*  
756 *Protocols* 4:44-57.

757 32. Nakayasu ES, Nicora CD, Sims AC, Burnum-Johnson KE, Kim Y-M, Kyle JE,  
758 Matzke MM, Shukla AK, Chu RK, Schepmoes AA, Jacobs JM, Baric RS, Webb-  
759 Robertson B-J, Smith RD, Metz TO. 2016. MPLEX: a Robust and Universal  
760 Protocol for Single-Sample Integrative Proteomic, Metabolomic, and Lipidomic  
761 Analyses. *mSystems* 1:e00043-16.

762 33. Coelho C, Brown L, Maryam M, Vij R, Smith DFQ, Burnet MC, Kyle JE, Heyman  
763 HM, Ramirez J, Prados-Rosales R, Lauvau G, Nakayasu ES, Brady NR,

764 Hamacher-Brady A, Coppens I, Casadevall A. 2019. Listeria monocytogenes  
765 virulence factors, including listeriolysin O, are secreted in biologically active  
766 extracellular vesicles. *Journal of Biological Chemistry* 294:1202-1217.

767 34. Nakayasu ES, Nicora CD, Sims AC, Burnum-Johnson KE, Kim YM, Kyle JE,  
768 Matzke MM, Shukla AK, Chu RK, Schepmoes AA, Jacobs JM, Baric RS, Webb-  
769 Robertson BJ, Smith RD, Metz TO. 2016. MPLEX: a Robust and Universal  
770 Protocol for Single-Sample Integrative Proteomic, Metabolomic, and Lipidomic  
771 Analyses. *mSystems* 1.

772 35. Kyle JE, Crowell KL, Casey CP, Fujimoto GM, Kim S, Dautel SE, Smith RD,  
773 Payne SH, Metz TO. 2017. LIQUID: an-open source software for identifying lipids  
774 in LC-MS/MS-based lipidomics data. *Bioinformatics* 33:1744-1746.

775 36. Pluskal T, Castillo S, Villar-Briones A, Oresic M. 2010. MZmine 2: modular  
776 framework for processing, visualizing, and analyzing mass spectrometry-based  
777 molecular profile data. *BMC Bioinformatics* 11:395.

778 37. Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates,  
779 individualized p.p.b.-range mass accuracies and proteome-wide protein  
780 quantification. *Nat Biotechnol* 26:1367-72.

781 38. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W,  
782 Selbach M. 2011. Global quantification of mammalian gene expression control.  
783 *Nature* 473:337-42.

784 39. Zamith-Miranda D, Heyman HM, Cleare LG, Couvillion SP, Clair GC, Bredeweg  
785 EL, Gacser A, Nimrichter L, Nakayasu ES, Nosanchuk JD. 2019. Multi-omics  
786 Signature of *Candida auris*, an Emerging and Multidrug-Resistant Pathogen.  
787 *mSystems* 4.

788 40. Howe EA, Sinha R, Schlauch D, Quackenbush J. 2011. RNA-Seq analysis in  
789 MeV. *Bioinformatics* 27:3209-10.

790 41. Gu Z, Eils R, Schlesner M. 2016. Complex heatmaps reveal patterns and  
791 correlations in multidimensional genomic data. *Bioinformatics* 32:2847-2849.

792 42. Huang da W, Sherman BT, Lempicki RA. 2009. Bioinformatics enrichment tools:  
793 paths toward the comprehensive functional analysis of large gene lists. *Nucleic  
794 Acids Res* 37:1-13.

795 43. Lutz MB, Kukutsch N, Ogilvie ALJ, Rößner S, Koch F, Romani N, Schuler G.  
796 1999. An advanced culture method for generating large quantities of highly pure  
797 dendritic cells from mouse bone marrow. *Journal of Immunological Methods*  
798 223:77-92.

799 44. Karkowska-Kuleta J, Kulig K, Karnas E, Zuba-Surma E, Woznicka O, Pyza E,  
800 Kuleta P, Osyczka A, Rapala-Kozik M, Kozik A. 2020. Characteristics of  
801 Extracellular Vesicles Released by the Pathogenic Yeast-Like Fungi *Candida*  
802 *glabrata*, *Candida parapsilosis* and *Candida tropicalis*. *Cells* 9:1722.

803 45. Peres da Silva R, Puccia R, Rodrigues ML, Oliveira DL, Joffe LS, Cesar GV,  
804 Nimrichter L, Goldenberg S, Alves LR. 2015. Extracellular vesicle-mediated  
805 export of fungal RNA. *Sci Rep* 5:7763.

806 46. Alves LR, Peres da Silva R, Sanchez DA, Zamith-Miranda D, Rodrigues ML,  
807 Goldenberg S, Puccia R, Nosanchuk JD. 2019. Extracellular Vesicle-Mediated  
808 RNA Release in *Histoplasma capsulatum*. *mSphere* 4:e00176-19.

809 47. Peres da Silva R, Longo LGV, Cunha JPCd, Sobreira TJP, Rodrigues ML, Faoro  
810 H, Goldenberg S, Alves LR, Puccia R. 2019. Comparison of the RNA Content of  
811 Extracellular Vesicles Derived from *Paracoccidioides brasiliensis* and  
812 *Paracoccidioides lutzii*. *Cells* 8:765.

813 48. Barman A, Gohain D, Bora U, Tamuli R. 2018. Phospholipases play multiple  
814 cellular roles including growth, stress tolerance, sexual development, and  
815 virulence in fungi. *Microbiological Research* 209:55-69.

816 49. Wachtler B, Wilson D, Haedicke K, Dalle F, Hube B. 2011. From attachment to  
817 damage: defined genes of *Candida albicans* mediate adhesion, invasion and  
818 damage during interaction with oral epithelial cells. *PLoS One* 6:e17046.

819 50. Maza PK, Bonfim-Melo A, Padovan ACB, Mortara RA, Orikaza CM, Ramos LMD,  
820 Moura TR, Soriano FM, Almeida RS, Suzuki E, Bahia D. 2017. *Candida albicans*:  
821 The Ability to Invade Epithelial Cells and Survive under Oxidative Stress Is  
822 Unlinked to Hyphal Length. *Frontiers in Microbiology* 8.

823 51. Mikamo H, Yamagishi Y, Sugiyama H, Sadakata H, Miyazaki S, Sano T, Tomita  
824 T. 2018. High glucose-mediated overexpression of ICAM-1 in human vaginal  
825 epithelial cells increases adhesion of *Candida albicans*. *J Obstet Gynaecol*  
826 38:226-230.

827 52. Moyes DL, Richardson JP, Naglik JR. 2015. *Candida albicans*-epithelial  
828 interactions and pathogenicity mechanisms: scratching the surface. *Virulence*  
829 6:338-346.

830 53. Bielska E, Sisquella MA, Aldeieg M, Birch C, O'Donoghue EJ, May RC. 2018.  
831 Pathogen-derived extracellular vesicles mediate virulence in the fatal human  
832 pathogen *Cryptococcus gattii*. *Nat Commun* 9:1556.

833 54. Romani L. 2011. Immunity to fungal infections. *Nat Rev Immunol* 11:275-88.

834 55. Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D, Gorospe M. 2017. RNA in  
835 extracellular vesicles. *WIREs RNA* 8:e1413.

836 56. Lambertz U, Oviedo Ovando ME, Vasconcelos EJR, Unrau PJ, Myler PJ, Reiner  
837 NE. 2015. Small RNAs derived from tRNAs and rRNAs are highly enriched in  
838 exosomes from both old and new world *Leishmania* providing evidence for  
839 conserved exosomal RNA Packaging. *BMC Genomics* 16:151.

840 57. Garcia-Silva MR, Cura das Neves RF, Cabrera-Cabrera F, Sanguinetti J,  
841 Medeiros LC, Robello C, Naya H, Fernandez-Calero T, Souto-Padron T, de  
842 Souza W, Cayota A. 2014. Extracellular vesicles shed by *Trypanosoma cruzi* are  
843 linked to small RNA pathways, life cycle regulation, and susceptibility to infection  
844 of mammalian cells. *Parasitology Research* 113:285-304.

845 58. Garcia-Silva MR, Cabrera-Cabrera F, das Neves RF, Souto-Padron T, de Souza  
846 W, Cayota A. 2014. Gene expression changes induced by *Trypanosoma cruzi*  
847 shed microvesicles in mammalian host cells: relevance of tRNA-derived halves.  
848 *Biomed Res Int* 2014:305239.

849 59. Chiou N-T, Kageyama R, Ansel KM. 2018. Selective Export into Extracellular  
850 Vesicles and Function of tRNA Fragments during T Cell Activation. *Cell Reports*  
851 25:3356-3370.e4.

852 60. Noble SM, French S, Kohn LA, Chen V, Johnson AD. 2010. Systematic screens  
853 of a *Candida albicans* homozygous deletion library decouple morphogenetic  
854 switching and pathogenicity. *Nature Genetics* 42:590-598.

855 61. Rittershaus PC, Kechichian TB, Allegood JC, Merrill AH, Hennig M, Luberto C,  
 856 Del Poeta M. 2006. Glucosylceramide synthase is an essential regulator of  
 857 pathogenicity of *Cryptococcus neoformans*. *The Journal of Clinical Investigation*  
 858 116:1651-1659.

859 62. Raj S, Nazemidashtarjandi S, Kim J, Joffe L, Zhang X, Singh A, Mor V,  
 860 Desmarini D, Djordjevic J, Raleigh DP, Rodrigues ML, London E, Del Poeta M,  
 861 Farnoud AM. 2017. Changes in glucosylceramide structure affect virulence and  
 862 membrane biophysical properties of *Cryptococcus neoformans*. *Biochimica et*  
 863 *Biophysica Acta (BBA) - Biomembranes* 1859:2224-2233.

864 63. Xisto MIDdS, Henao JEM, Dias LdS, Santos GMP, Calixto RdOR, Bernardino  
 865 MC, Taborda CP, Barreto-Bergter E. 2019. Glucosylceramides From  
 866 *Lomentospora prolificans* Induce a Differential Production of Cytokines and  
 867 Increases the Microbicidal Activity of Macrophages. *Frontiers in Microbiology* 10.

868 64. Ahn EH, Yang H, Hsieh C-Y, Sun W, Chang C-C, Schroeder JJ. 2019.  
 869 Evaluation of chemotherapeutic and cancer-protective properties of sphingosine  
 870 and C2-ceramide in a human breast stem cell derived carcinogenesis model. *Int*  
 871 *J Oncol* 54:655-664.

872 65. Chou H-L, Lin Y-H, Liu W, Wu C-Y, Li R-N, Huang H-W, Chou C-H, Chiou S-J,  
 873 Chiu C-C. 2019. Combination Therapy of Chloroquine and C2-Ceramide  
 874 Enhances Cytotoxicity in Lung Cancer H460 and H1299 Cells. *Cancers* 11:370.

875 66. Peter C, Waibel M, Radu CG, Yang LV, Witte ON, Schulze-Osthoff K,  
 876 Wesselborg S, Lauber K. 2008. Migration to Apoptotic "Find-me" Signals Is  
 877 Mediated via the Phagocyte Receptor G2A. *Journal of Biological Chemistry*  
 878 283:5296-5305.

879 67. Silva-Neto MA, Lopes AH, Atella GC. 2016. Here, There, and Everywhere: The  
 880 Ubiquitous Distribution of the Immunosignaling Molecule  
 881 Lysophosphatidylcholine and Its Role on Chagas Disease. *Front Immunol* 7:62.

882 68. Tounsi N, Meghari S, Moser M, Djerdjouri B. 2015. Lysophosphatidylcholine  
 883 exacerbates *Leishmania* major-dendritic cell infection through interleukin-10 and  
 884 a burst in arginase1 and indoleamine 2,3-dioxygenase activities. *International*  
 885 *Immunopharmacology* 25:1-9.

886 69. Moyes DL, Richardson JP, Naglik JR. 2015. *Candida albicans*-epithelial  
 887 interactions and pathogenicity mechanisms: scratching the surface. *Virulence*  
 888 6:338-46.

889 70. Casadevall A, Kontoyiannis DP, Robert V. 2019. On the Emergence of *Candida*  
 890 *auris*: Climate Change, Azoles, Swamps, and Birds. *mBio* 10.

891

892 **Table 1. Gene ontology for RNAs enriched in EVs from *C. auris* and *C. albicans***

***C. auris***

Name	Protein names	TPM mean	Log <sub>2</sub> fold change	FDR p-value
CAALFM_C109220WA	MFS domain-containing protein	1112.50	6.50	0.00%

CAALFM_C112570CA	Elongator subunit	1357.63	6.63	0.00%
CAALFM_C207040WA	HIT-type domain-containing protein	953.50	4.06	0.06%
POX18	Pox18p	809.32	6.06	0.00%
CAALFM_C111080WA	6-phosphofructo-2-kinase	494.49	2.87	1.39%
RBP1	FK506-binding protein 1 (FKBP) (EC 5.2.1.8) (Peptidyl-prolyl cis-trans isomerase) (PPIase) (Rapamycin-binding protein)	1586.55	8.36	0.00%
MET1	Uroporphyrinogen-III C-methyltransferase	1103.00	3.23	0.05%
STE24	CAAX prenyl protease (EC 3.4.24.84)	422.40	5.87	0.00%
RGS2	GTPase-activating protein	507.00	6.58	0.00%
CAALFM_C204870CA	THO complex subunit 2	238.36	5.07	0.00%
CAALFM_C114310WA	Deoxycytidine monophosphate deaminase	842.16	7.38	0.00%
RGS2	GTPase-activating protein	507.00	6.58	0.00%

### *C. albicans*

Name	Protein names	TPM mean	Log <sub>2</sub> fold change	FDR p-value
TAR1	Tar1p	14740.21	-14.32	0.00%
CDC42	Cell division control protein 42 homolog	2280.43	-3.90	0.01%
THR4	Threonine synthase (EC 4.2.3.1)	1486.19	-5.44	0.00%
THS1	Threonyl-tRNA synthetase (EC 6.1.1.3)	1624.40	-5.15	0.00%
PHHB	4a-hydroxytetrahydrobiopterin dehydratase (EC 4.2.1.96)	1763.12	-6.29	0.00%
CAALFM_CR02690WA	CAP-Gly domain-containing protein	753.92	-4.94	0.00%
CAALFM_C107850CA	Anaphase promoting complex subunit	1198.57	-3.16	0.26%
GCN20	Putative AAA family ATPase	1083.26	-3.31	0.05%
CAALFM_C501410CA	ER membrane protein complex subunit 1	392.62	-3.33	0.01%
POM152	Pom152p	390.75	-3.55	0.00%
MRPL8	Mitochondrial 54S ribosomal protein YmL8	559.14	-4.39	0.00%
CAALFM_C100200CA	RRM domain-containing protein	341.91	-3.17	0.00%